Your web browser might not support this type of content. In order to preview our demo please make sure you have Flash Player enabled on your browser or try using a different web browser.

Teva returns to the market after opioid controversy with USD/EUR dual-tranche

20 Nov 2019

Teva Pharmaceutical (Ba2/BB/BB) returned to the international markets yesterday (19 November) with a dual tranche USD/EUR for a combined size of USD2.1bn, equivalent. The company has had a challenging year as it attempted to mitigate its connection

This content is restricted, to subscribe or register for a free trial please contact , +44 20 7832 0826 or click below.

Sign up here

Already registered?

Login to your account
Back
More »
More »

Register for Free Trial

Free Trial






Already registered?

Login to your account